Literature DB >> 2392504

Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.

S Boyce1, N M Rupniak, M J Steventon, S D Iversen.   

Abstract

Intermittent treatment with L-dopa over a 2-year period induced abnormal involuntary movements in MPTP-treated squirrel monkeys. Dyskinesias included a choreic and dystonic component. Dose-response curves for chorea and dystonia revealed that the same dose of L-dopa (30 mg/kg) induced the highest score for both dyskinesias: however, the severity was much greater for chorea. Choreic movements were always most prevalent at the time of peak effect, whereas dystonia was apparent at the time of peak effect and at "end-of-dose", and was occasionally observed spontaneously. Our findings indicate that squirrel monkeys treated with MPTP develop L-dopa-induced dyskinesias which closely resemble those observed in Parkinson's disease. This species provides a valuable animal model to develop improved therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2392504     DOI: 10.1007/bf02245739

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.

Authors:  N M Rupniak; S J Tye; C A Jennings; A E Loper; J V Bondi; M Hichens; E Hand; S D Iversen; S M Stahl
Journal:  Neurology       Date:  1989-03       Impact factor: 9.910

2.  Physostigmine in choreiform movement disorders.

Authors:  D Tarsy; N Leopold; D S Sax
Journal:  Neurology       Date:  1974-01       Impact factor: 9.910

3.  Autoradiographic localization of dopamine D1 binding sites in areas receiving striatal input.

Authors:  W C Graham; A R Crossman
Journal:  Eur J Pharmacol       Date:  1987-10-27       Impact factor: 4.432

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus.

Authors:  R G Robertson; S M Farmery; M A Sambrook; A R Crossman
Journal:  Brain Res       Date:  1989-01-09       Impact factor: 3.252

6.  Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias.

Authors:  H L Klawans; W J Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

7.  The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias.

Authors:  S M Stahl; K L Davis; P A Berger
Journal:  J Clin Psychopharmacol       Date:  1982-10       Impact factor: 3.153

8.  Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor.

Authors:  G U Corsini; P Onali; C Masala; C Cianchetti; A Mangoni; G Gessa
Journal:  Arch Neurol       Date:  1978-01

9.  Comparative distribution of dopamine D-1 and D-2 receptors in the basal ganglia of turtles, pigeons, rats, cats, and monkeys.

Authors:  E K Richfield; A B Young; J B Penney
Journal:  J Comp Neurol       Date:  1987-08-15       Impact factor: 3.215

Review 10.  Acute dystonia induced by neuroleptic drugs.

Authors:  N M Rupniak; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

View more
  9 in total

1.  Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.

Authors:  Yunmin Ding; Jacqueline Restrepo; Lisa Won; Dong-Youn Hwang; Kwang-Soo Kim; Un Jung Kang
Journal:  Neurobiol Dis       Date:  2007-04-10       Impact factor: 5.996

Review 2.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 3.  Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers.

Authors:  Véronique Sgambato; Léon Tremblay
Journal:  J Neural Transm (Vienna)       Date:  2018-03-03       Impact factor: 3.575

Review 4.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

Review 5.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

6.  Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.

Authors:  H Przuntek; D Welzel; M Gerlach; E Blümner; W Danielczyk; H J Kaiser; P H Kraus; H Letzel; P Riederer; K Uberla
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

7.  Oral movement patterns induced in rats by local infusions into striatum depend upon the regimen of prior neuroleptic exposure.

Authors:  G Ellison; U Liminga; A Keys
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

8.  L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates.

Authors:  M Kuoppamäki; G Al-Barghouthy; M J Jackson; L A Smith; N Quinn; P Jenner
Journal:  J Neural Transm (Vienna)       Date:  2007-04-20       Impact factor: 3.575

Review 9.  Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.

Authors:  Xiomara A Perez
Journal:  Neuropsychol Rev       Date:  2015-11-09       Impact factor: 7.444

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.